CSA/MMF/steroids versus CSA/AZA/steroids with and without basiliximab in cadaveric kidney transplantation.
Boggi
U
U
Divisione di Chirurgia Generale e Trapianti, Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina, Università di Pisa, Italy.
Vistoli
F
F
Del Chiaro
M
M
Bartolo
T V
TV
Rizzo
G
G
Mosca
F
F
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use*; D000077552:Basiliximab; D002102:Cadaver; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use*; D014019:Tissue Donors
D000911:Antibodies, Monoclonal; D011993:Recombinant Fusion Proteins; D013256:Steroids; D016572:Cyclosporine; D000077552:Basiliximab; D009173:Mycophenolic Acid; D001379:Azathioprine